During the Heart Rhythm Society’s 37th Annual Scientific Sessions, which runs May 4-6, 2016, more than 1,000 new research studies will be shared as researchers, scientist, clinicians and innovators collaborate to solve the health problems that heart rhythm disorders cause for patients.
“You can expect to see the latest new developments, technology and science in the heart rhythm field,” said John Day, MD, interventional cardiologist with the Intermountain Medical Center Heart Institute and outgoing president of the Heart Rhythm Society. “I’m especially excited about this year’s live cases, which will be broadcast from Intermountain Medical Center in Salt Lake City.”
An arrhythmia is an abnormal heart rhythm that affects many people. It may feel like fluttering or a brief pause. It may be so brief that it doesn’t change your overall heart rate (the number of times per minute that your heart beats). Or it can cause the heart rate to be too slow or too fast. Some arrhythmias don’t cause any symptoms. Others can make you feel lightheaded or dizzy.
Millions of people experience irregular heartbeats, called arrhythmias, at some point in their lives. Most of the time, they are harmless and happen in healthy people free of heart disease. However, some abnormal heart rhythms can be serious or even deadly. Having other types of heart disease can also increase the risk of arrhythmias.
On Thursday, May 5, from 10:30 a.m. to noon (Pacific Time), two live cases will be broadcast from Intermountain Medical Center’s Heart Institute to the Main Stage – Level 3 of the Moscone Center in San Francisco.
- CASE 1: A complex lead extraction from both the right and left side of the heart, including an orphaned lead. The case will also highlight the new superior vena cava rescue balloon to aid in the event of a superior vena cava tear.
- CASE 2: Atrial fibrillation ablation
Additional research studies being presented at the conference by the Intermountain Medical Center Heart Institute include:
- Atrial fibrillation patients treated with long-term Warfarin anticoagulation have higher rates of all dementia types compared to patients receiving Warfarin long-term for other indications (Thursday, May 5, 10 a.m., Epicenter Theater 1, Hall D)
- Age at time of ablation and long-term risk of atrial fibrillation in adult Wolff-Parkinson-White Syndrome patients treated with and without catheter ablation (Thursday, May 5, 9 a.m. to noon, Epicenter, Hall D)
- Variability in long-term anticoagulation effect with Warfarin strongly increases risk of renal dysfunction in atrial fibrillation patients (Thursday, May 5, 9 a.m. to noon, Epicenter, Hall D)
“During the conference, people can learn the latest techniques from the world’s best experts using the latest technology,” said Dr. Day. “It’s something you definitely won’t want to miss.”